purple coneflower
Skip this Video
Download Presentation
Purple Coneflower

Loading in 2 Seconds...

play fullscreen
1 / 33

Purple Coneflower - PowerPoint PPT Presentation

  • Uploaded on

Purple Coneflower. Echinacea purpurea Echinacea angustifolia Echinacea pallida. Presented by: Henry Tran, Paul St. Romain, & Margaret Wells. Names of Echinacea. Family: Asteraceae Genus: Echinacea Greek origin: echinos = sea urchin or hedgehog

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Purple Coneflower' - paul2

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
purple coneflower

Purple Coneflower

Echinacea purpurea

Echinacea angustifolia

Echinacea pallida

Presented by: Henry Tran, Paul St. Romain, & Margaret Wells

names of echinacea
Names of Echinacea
  • Family: Asteraceae Genus: Echinacea
  • Greek origin: echinos = sea urchin or hedgehog
  • Perennial Plant; 1-2ft. Tall, spiny appearance
  • AKA: American Coneflower, Black Sampson, Comb Flower, Echinacea angustifolia, Echinacea pallida, Echinacea purpurea, Indian Head, Purple Coneflower, Rudbeckia, Sampson Head, Scurvy Root, Snakeroot, Helichroa (Rafinesque)
  • Original genus name = Rudbeckia
  • 1794 Conrad Moench used Echinacea , but not adopted by the scientific community until circa 1848
history of echinacea
History of Echinacea
  • Found in the U.S. & Canada
  • Home: Great Plains Region(from Texas into Canada and from the Rocky Mountains into Kentucky)
  • Other States/Regions:CO, IL, IA, KS, KY, LA, MN, MO, MT, NE, NM, ND, OK, SD, TX, WY; Canada (AB, MB,SK)
  • Used by Native Americans(i.e. Blackfoot, Lakota, Choctaw, Delaware, Cheyenne, Comanche, Sioux & Dakota)
  • E. purpurea, E. angustifolia, and E. pallida
  • Blackfoot & Lakota used E. angustifolia as toothache remedy(isobutylamides found in root which creates numbing sensation)
historical uses
Historical Uses
  • E. purpurea used by Choctaw as cough medicine and as G.I. aid
  • Delaware for venereal disease; Comanche use for sore throat & toothache
  • E. pallida used by western tribes (Cheyenne used it for antirheumatic, cold remedy, & as dermatological aid; Decoction of the root as vermifuge & eye medicine; Sioux use for analgesic properties & for snake bites)
  • Used for a wide variety of conditions(18th,19th, early 20th by American Settlers for infections and inflammation)
  • First Written Record in 1762; Flora Virginica (John Clayton)
  • Eclectic Physicians first to realize therapeutic benefits of E. purpurea
  • “Red Sunflower” in Dispensatory of Eclectic Physcians in 1852; recommended use for patients with syphilis
  • Eclectic Physicians and Topical Wound Healing (1950’s)
introduction to euro american society
Introduction to Euro-American Society
  • Dr. H.C. F. Meyer sent J.Lloyd (Lloyd Brothers Pharmaceuticals) & Dr. J. King sample of root
  • “Meyers Blood Purifier” in 1885
  • 1886 E. angustifolia arrives for Lloyd & King
  • Lloyd sets out to negate claims via pharmaceutical tests
  • Favorable results
  • 1887 King statement in The Eclectic Medical Journal “…should it be found to contain only one-half the virtues he (H.C. F. Meyer) attributes to it, it will form an important addition to our materia medica.”
  • Lloyd Pharmaceuticals; multiple products (creams, liquids & mouth wash);Fermentation & Echafolta
historical uses con t
Historical Uses Con’t.
  • In 1910, decline in U.S. use began due to 3 reasons
  • First = A. Flexner comparison study of allopathic vs. faltering botanico-medical education
  • Second = Direct results of antibiotics vs. general immune response of Eichinacea species
  • Third major reason = Hostility among practitioners
  • Patentable antibiotics
  • 1916-1947 E. angustifolia & E. pallida root & rhizome recognized by the U.S. National Formulary (NF)
  • 1910 only 47% of USP was based on medicinal plant drugs
german research commission e
German Research & Commission E
  • German equivalent to our FDA
  • 1920’s Gerhard Madaus; 1930’s to present extensive German research (peaked in 80’s)
  • Research done on common communicable diseases & immune response
  • Two varieties approved (E. Purpurea & E. Pallida, but not roots)
  • Believed that E. Angustifolia is stronger (problem = no official clinical data to support claim)
  • PDR for Herbal Medicines states multiple uses (used as treatment for common colds, bronchitis, UTI’s, mouth & pharynx inflammation, wounds, burns & weak I.S.)
active components
Active Components
  • Polysaccharides
    • 4-0-methylglucuronoarabinoxylan
    • Rhamnoarabinogalactin
  • Polyacetylenes
  • Alkylamides (echinaceine)
parts used administration
Parts Used & Administration
  • Parts of plant that are used: aboveground roots, rhizome & leaves
  • In U.S. used as tea, squeezed (expressed) juice (alcohol and/or glycerin based), capsules (herbal powder for URI), tincture (gargling & swallowing), topically, & as an injection (not recommended in U.S.)
  • In Germany many times administered intravenously along with traditional medical treatments
  • Dosage, type of administration, & duration of treatment vary in patient care
present day future hopes
Present Day & Future Hopes
  • U.S. research peaked again in 1990’s to present
  • DSHEA act & active research (NCCAM)
  • Journal: Economic Medicinal Plant Research(through 1991; 360 studies on Echinacea)
  • Extremely Popular & Profitable
  • Some studies show it does help I.S., “septic” conditions, & increases hyaluronic acid when topically applied
  • Echinacin ointment for inflammatory skin diseases
  • Need more clinical trials & dosage specifications
  • Hope of proving effectiveness on immune system
  • Common Cold
  • Cancer prevention
the cold
The Cold
  • What is it?
  • Symptoms
  • Duration


  • Inhaled particles
  • Cold virus attachment
  • Incubation period: 8-12 hours
  • Peak of symptoms: 36-72 hours
neat facts about colds
Neat facts about colds
  • Infection rate
  • Being cold?
  • Feed a cold, starve a fever
  • Children
research echinacea the common cold
Research – Echinacea & the Common cold
  • Is it effective?
  • Is it worth it?
  • Is it toxic?
  • Positive results
    • Reduced symptoms and duration
  • Negative results
    • Not useful for prevention
why contradictory research
Why contradictory research?
  • Hard to quantitatively measure symptoms
  • Psychological effects vary
  • Many different types of cold viruses
  • Preparations are not standardized
  • Meta analysis
  • Significantly important difference – is treatment worth it based on cost, effect and duration of infection?
  • Echinacea: 2nd to Vitamin C – people thought it would be worth it if it reduced colds by 36.8 hours
  • Zinc and prescription in 60 to 90 hour range
reactions toxicity
Reactions & Toxicity
  • Could negatively affect patients with progressive systemic diseases & autoimmune disorders (i.e. tuberculosis, lupus & connective tissues disorders, HIV/AIDS), pregnant women & children under two years of age
  • Patients with asthma & atopy (genetic tendency to have allergic reactions) are more susceptible
  • According to NCCAM website; rare allergic reactions found to be rashes, increased asthma and anaphylaxis
  • Allergic reaction possible if person is allergic to plants in daisy family (i.e. ragweed, chrysanthemums, marigolds & daisies)
  • Gastrointestinal side effect most common in studies
mode of action
Mode of Action
  • Bioactive substances capable of stimulating innate immunity.
  • What is the innate immune response?
    • Nonspecific

Macrophages stimulated to release cytokines and chemokines that initiate inflammatory response

  • Cytokines cause dilation of local small blood vessels and changes in endothelial cells
  • Lead to movement of leukocytes (neutrophils and monocytes) from to blood vessels into the infected tissue
  • Leucocytes are guided by chemokines produced by macrophages
  • Blood vessels become more permeable, allowing plasma proteins and fluid to leak into the tissues
mode of action cont
Mode of Action cont.
  • Immune response ascribed to polyssacharides
  • Study: Incubation of human macrophages with purified polysaccharide:
      • Increased the motility of granulocytes and their cytotoxic activity against staphylococci
      • Stimulated proliferation of human lymphocytes
      • Induced production of TNF-a, IL-1, and IL-6

Purified polysaccharides from E. purpurea induced macrophage production of IL-1, IL-6, and TNF-a

Figure 8-22

mode of action cont1
Mode of Action, cont.
  • Evidence supporting polysaccharide function of extract:
    • Augmented the phagocytosis of yeast particles or opsonized zymosan by human granulocytes by 23% and 34%
    • Intravenous treatment of mice:
      • Mice injected with lethal doses of Candida albicans and Listeria monocytogenes
      • Treatment significantly increased survival rate of both healthy and immunosuppressed mice.
mode of action cont2
Mode of Action, cont.
  • Akylamides from Echinacea:
    • Modulate TNF-a mRNA expression in human monocytes and macrophages via the CB2 cannabinoid receptor
    • Bind to CB2 more strongly than endogenous cannabinoids
      • Dodeca-2E,4E,8Z,10Z-tetrenoic acid isobutylamide (A1)
      • Docea-2E,4E-dienoic acid isobutylamide (A2)
mode of action cont3
Mode of Action, cont.
  • Anti-inflammatory effects
    • Lipoxygenase (LOX) and cyclooxygenase (COX) inhibition
    • Polysaccharide fraction known to inhibit the action of the enzyme hyaluronidase
    • Echinacoside provides protective effect against free radical induced degradation of collagen
  • Echinacea appears to activate non-specific cellular and humoral immunity and the complement system by increasing the production and activity of:
    • Leukocytes
      • Granulocytes
      • Lymphocytes
      • Monocytes
    • Cytokines

1. Echinacea. 2006 [cited 2006 04/23/06]; A database summarizing the research on various supplements. Part of the site is member only.]. Available from: http://supplementwatch.com/suplib/supplement.asp?DocId=1101&templateId=100.

2. Agnew, L.L., et al., Echinacea intake induces an immune response through altered expression of leucocyte hsp70, increased white cell counts and improved erythrocyte antioxidant defences. J Clin Pharm Ther, 2005. 30(4): p. 363-9.

3. Barnes, J., et al., Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol, 2005. 57(8): p. 929-54.

4. Barrett, B., et al., Using benefit harm tradeoffs to estimate sufficiently important difference: the case of the common cold. Med Decis Making, 2005. 25(1): p. 47-55.

5. Barrett, B.P., et al., Treatment of the common cold with unrefined echinacea. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 2002. 137(12): p. 939-46.

Borchers, A.T., et al., Inflammation and Native American medicine: the role of botanicals. Am J Clin Nutr, 2000. 72(2): p. 339-47.

7. Flannery, M.A. 1999. From Rudbeckia to Echinacea: The Emergence of the Purple Cone Flower in Modern Therapeutics, Pharmacy in History, Vol. 41 (2):52-58

8. Flannery, M.A. 2004. Civil War Pharmacy: A History of Drugs, Drug Supply and Provision, and Therapeutics for the Union and Confederacy. The Haworth Press, Inc, Binghamton, NY.

9. Goel, V., et al., Efficacy of a standardized echinacea preparation (Echinilin) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther, 2004. 29(1): p. 75-83.

10. Jack M. Gwaltney, M., Frederick G. Hayden, MD Common Cold. 1999-2005 [cited 2006 04/23/06]; General information over the common cold drawn from over 70 medical resources]. Available from: http://www.commoncold.org/index.htm.


11. Kim, L.S., R.F. Waters, and P.M. Burkholder, Immunological activity of larch arabinogalactan and Echinacea: a preliminary, randomized, double-blind, placebo-controlled trial. Altern Med Rev, 2002. 7(2): p. 138-49.

12. Kligler, B., Echinacea. Am Fam Physician, 2003. 67(1): p. 77-80.

13. Linde, K., et al., Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev, 2006(1): p. CD000530.

14. Raduner, S., et al., Alkylamides from Echinacea are a new class of cannabinomimetics - CB2-receptor dependent and independent immunomodulatory effects. J Biol Chem, 2006.

Sperber, S.J., et al., Echinacea purpurea for prevention of experimental rhinovirus colds. Clin Infect Dis, 2004. 38(10): p. 1367-71.

Turner, R.B., et al., An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med, 2005. 353(4): p. 341-8.

Website: http://nccam.nih.gov/health/echinacea/#intro. 2005. Herbs at a Glance: Echinacea. NCCAM Publication No. D271.